1 / 37

Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence

Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence. Program Goals. Insulin Deficiency and Glucagon Hypersecretion in T2D. Postprandial Glucagon Is Excessive and Not Corrected by Exogenous Insulin. Incretin Hormome Physiology. Signal Transduction and GLP-1.

blaze-rowe
Download Presentation

Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence

  2. Program Goals

  3. Insulin Deficiency and Glucagon Hypersecretion in T2D

  4. Postprandial Glucagon Is Excessive and Not Corrected by Exogenous Insulin

  5. Incretin Hormome Physiology

  6. Signal Transduction and GLP-1

  7. Summary of Main GLP-1 Effects

  8. 2012 ADA/EASD Position Statement

  9. Impact of Exenatide Twice-Daily Therapy Over 3 Years: Effect on HbA1c and Body Weight

  10. Considerations in Choosing a GLP-1 Receptor Agonist

  11. EXN Once Weekly vs Sitagliptin and Pioglitazone: HbA1c Reduction

  12. Nausea With GLP-1 Receptor Agonists Tends to Decrease With Time

  13. Strategies to Minimize the Occurrence of Nausea

  14. Minor Hypoglycemia* With GLP-1 Receptor Agonists

  15. Liraglutide/Exenatide: Black Box WarningRisk of Thyroid C-Cell Tumors

  16. Incretin-based Therapies:Concern About Acute Pancreatitis

  17. Sitagliptin and Exenatide Associated With Increased Risk for Hospitalization for Acute Pancreatitis

  18. Incretin-based Therapies: Renal Impairment

  19. Incretin-based Therapies Associated With Increased Alpha-Cell Hyperplasia

  20. Exenatide Twice Daily Added to Insulin Glargine

  21. Closing Comments

  22. Abbreviations

  23. Abbreviations (cont)

  24. Abbreviations (cont)

  25. References

  26. References (cont)

  27. References (cont)

  28. References (cont)

  29. References (cont)

  30. References (cont)

More Related